论文信息 - Brolucizumab 12- and 16-Week Fixed Dosing Potential in Neovascular AMD: A post hoc Evaluation of Data from the HAWK and HARRIER Trials - 字舞流文

Brolucizumab 12- and 16-Week Fixed Dosing Potential in Neovascular AMD: A post hoc Evaluation of Data from the HAWK and HARRIER Trials

G. Querques | A. Clemens | Z. Mulyukov | A. Wolf | J. Chhablani | A. Khanani | R. Flores | M. Singer | K. Gedif | Guruprasad B | Xiaoxiao Liu